Secondary Prevention of Osteoporosis

• Status: Completed
• Trial end date: 2008-06-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to develop and implement an evidence based protocol for the secondary prevention of osteoporotic fractures and falls, and to determine how compliance with this intervention improves muscle strength and functional status following a fracture.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Hebrew Rehabilitation Center, Boston; Hebrew SeniorLife
• Collaborators: GlaxoSmithKline; Merck Sharp & Dohme Corp.; National Institute on Aging (NIA)
• Treatments: Alendronate; Calcium; Calcium Carbonate; Calcium, Dietary; Cholecalciferol

Criteria

Inclusion Criteria:

• Admitted to rehab unit with the primary or secondary diagnosis of fracture

• English speaking

• Cognitively able to provide consent or health care proxy available and willing to provide consent

• Willing to cooperate

Exclusion Criteria:

• Pathologic or periprosthetic fractures

• Creatinine clearance less than 15ml/minute

• Severe hypocalcemia

• Esophageal stricture or achalasia

• Taking other treatment for osteoporosis besides calcium or vitamin D in the past 6-months

• History of kidney stones in the past 6-months